NEW YORK (AP) — Pharmaceutical companies have agreed to slash the Medicare prices for 15 prescription drugs after months of negotiations, anticipated to generate billions in savings for taxpayers and older adults, the Trump administration stated. However, the net prices disclosed for a 30-day supply of each drug do not reflect the out-of-pocket costs that Medicare recipients will pay at the pharmacy, which depend on individual plans and annual prescription expenditures.
Health Secretary Robert F. Kennedy Jr. highlighted the agreements as part of the administration’s efforts to improve affordability for Americans. The Medicare drug negotiation program, which made these deals possible, was initiated under Joe Biden’s administration and mandated by law.
“President Trump directed us to stop at nothing to lower health care costs for the American people,” Kennedy remarked. “As we work to Make America Healthy Again, we will leverage every tool to deliver affordable health care to seniors.”
This announcement concludes a second round of negotiations under a 2022 law that enables Medicare to negotiate prices for the most used and costly prescription drugs among older Americans, raising the total negotiated drug prices to 25. The new prices will take effect in 2027, following the initial round negotiated under Biden, which is set to be effective in January.
The latest price negotiations include key medications such as the widely used GLP-1 weight-loss and diabetes drugs like Ozempic, Rybelsus, and Wegovy, among others that treat asthma, diabetes, irritable bowel syndrome, and various cancers.
Dr. Mehmet Oz, the Administrator of the Centers for Medicare and Medicaid Services, indicated that this administration's negotiations yielded improved results for taxpayers and seniors than prior negotiations.
According to previous assessments, the Biden administration's first negotiation round was projected to save approximately $6 billion, whereas the Trump administration claims its recent negotiations will save around $8.5 billion.
However, the exact savings for Medicare beneficiaries remain unclear, as they are influenced by individual circumstances. A new regulation has begun capping out-of-pocket drug costs for Medicare recipients at $2,000, projected to provide relief amounting to $685 million in estimated savings for those on drug plans.
Spencer Perlman, director of health care research at Veda Partners, stated that the improved outcomes likely stemmed from a better selection of negotiated drugs and lessons from the previous year.
While the GLP-1 drugs have drawn scrutiny for their costs, it remains to be seen how Medicare recipients will access these medications for obesity treatment, given that government coverage for weight-loss drugs has been historically prohibited. Nevertheless, a new pilot program aims to expand drug coverage for certain high-risk obese patients.
The Trump administration has also struck unrelated deals aimed at reducing drug costs for the broader population. Conversely, pharmaceutical companies have raised concerns, asserting that the Medicare drug negotiations violate free-market principles.
In statements released, Alex Schriver from the Pharmaceutical Research and Manufacturers of America warned that policies like the Inflation Reduction Act could jeopardize future medical innovations, claiming a potential $300 billion loss in biopharmaceutical research funding. Looking ahead, Medicare plans to negotiate prices for an additional group of 15 drugs next year.
Health Secretary Robert F. Kennedy Jr. highlighted the agreements as part of the administration’s efforts to improve affordability for Americans. The Medicare drug negotiation program, which made these deals possible, was initiated under Joe Biden’s administration and mandated by law.
“President Trump directed us to stop at nothing to lower health care costs for the American people,” Kennedy remarked. “As we work to Make America Healthy Again, we will leverage every tool to deliver affordable health care to seniors.”
This announcement concludes a second round of negotiations under a 2022 law that enables Medicare to negotiate prices for the most used and costly prescription drugs among older Americans, raising the total negotiated drug prices to 25. The new prices will take effect in 2027, following the initial round negotiated under Biden, which is set to be effective in January.
The latest price negotiations include key medications such as the widely used GLP-1 weight-loss and diabetes drugs like Ozempic, Rybelsus, and Wegovy, among others that treat asthma, diabetes, irritable bowel syndrome, and various cancers.
Dr. Mehmet Oz, the Administrator of the Centers for Medicare and Medicaid Services, indicated that this administration's negotiations yielded improved results for taxpayers and seniors than prior negotiations.
According to previous assessments, the Biden administration's first negotiation round was projected to save approximately $6 billion, whereas the Trump administration claims its recent negotiations will save around $8.5 billion.
However, the exact savings for Medicare beneficiaries remain unclear, as they are influenced by individual circumstances. A new regulation has begun capping out-of-pocket drug costs for Medicare recipients at $2,000, projected to provide relief amounting to $685 million in estimated savings for those on drug plans.
Spencer Perlman, director of health care research at Veda Partners, stated that the improved outcomes likely stemmed from a better selection of negotiated drugs and lessons from the previous year.
While the GLP-1 drugs have drawn scrutiny for their costs, it remains to be seen how Medicare recipients will access these medications for obesity treatment, given that government coverage for weight-loss drugs has been historically prohibited. Nevertheless, a new pilot program aims to expand drug coverage for certain high-risk obese patients.
The Trump administration has also struck unrelated deals aimed at reducing drug costs for the broader population. Conversely, pharmaceutical companies have raised concerns, asserting that the Medicare drug negotiations violate free-market principles.
In statements released, Alex Schriver from the Pharmaceutical Research and Manufacturers of America warned that policies like the Inflation Reduction Act could jeopardize future medical innovations, claiming a potential $300 billion loss in biopharmaceutical research funding. Looking ahead, Medicare plans to negotiate prices for an additional group of 15 drugs next year.
